2016
Infusion reactions are common after high-dose carmustine in BEAM chemotherapy and are not reduced by lengthening the time of administration
Perreault S, Baker J, Medoff E, Pratt K, Foss F, Isufi I, Seropian S, Cooper DL. Infusion reactions are common after high-dose carmustine in BEAM chemotherapy and are not reduced by lengthening the time of administration. Supportive Care In Cancer 2016, 25: 205-208. PMID: 27614867, DOI: 10.1007/s00520-016-3399-4.Peer-Reviewed Original ResearchAdolescentAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCarmustineCytarabineDose-Response Relationship, DrugDrug Administration ScheduleEtoposideFemaleHematopoietic Stem Cell TransplantationHumansInfusions, IntravenousMaleMelphalanMiddle AgedTransplantation ConditioningTransplantation, AutologousYoung Adult
2006
Outpatient high‐dose melphalan in multiple myeloma patients
Kassar M, Medoff E, Seropian S, Cooper DL. Outpatient high‐dose melphalan in multiple myeloma patients. Transfusion 2006, 47: 115-119. PMID: 17207239, DOI: 10.1111/j.1537-2995.2007.01073.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAmbulatory CareAnti-Bacterial AgentsAntibiotic ProphylaxisAntineoplastic Agents, AlkylatingBacteremiaCeftriaxoneDose-Response Relationship, DrugFeverHospitalizationHumansIncidenceLength of StayMelphalanMiddle AgedMultiple MyelomaNeutropeniaRetrospective StudiesStaphylococcal InfectionsStem Cell TransplantationConceptsHigh-dose melphalanOnset of neutropeniaPrimary care providersOutpatient settingMean durationPeripheral blood progenitor cell infusionGeneral outpatient settingProgenitor cell infusionTreatment-related mortalityMultiple myeloma patientsUse of ceftriaxoneApparent beneficial effectTransplant episodesMost patientsCell infusionFebrile patientsMedian timeMyeloma patientsRandomized trialsDecreased riskOutpatient therapyAmbulatory therapyOutpatient treatmentNeutropeniaCare providers
1999
Neutropenic infections in 100 patients with non-Hodgkin’s lymphoma or Hodgkin’s disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option
Seropian S, Nadkarni R, Jillella A, Salloum E, Burtness B, Hu G, Zelterman D, Cooper D. Neutropenic infections in 100 patients with non-Hodgkin’s lymphoma or Hodgkin’s disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option. Bone Marrow Transplantation 1999, 23: 599-605. PMID: 10217191, DOI: 10.1038/sj.bmt.1701610.Peer-Reviewed Original ResearchMeSH KeywordsAdultAmbulatory CareAntibiotic ProphylaxisAntineoplastic Combined Chemotherapy ProtocolsCarmustineCytarabineDose-Response Relationship, DrugHematopoietic Stem Cell TransplantationHodgkin DiseaseHumansLymphoma, Non-HodgkinMelphalanMiddle AgedNeutropeniaPodophyllotoxinRetrospective StudiesConceptsPeripheral blood progenitor cell transplantHigh-dose chemotherapyAbsolute neutrophil countProgenitor cell transplantCell transplantHodgkin's diseaseHodgkin's lymphomaHerpes simplex virus serologyHigh-dose BEAM chemotherapyGram-positive bacteremiaDuration of neutropeniaRisk of bacteremiaPeriod of neutropeniaMultivariate logistic regressionInvasive fungal infectionsRisk of developmentNumber of CD34Amphotericin therapyBEAM chemotherapyFebrile neutropeniaNeutropenic infectionOral ciprofloxacinWBC engraftmentProphylactic antibioticsCare visits